• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于 RNA 转录组和单细胞测序的免疫相关 PANoptosis lncRNA 模型在肾透明细胞癌中作用的综合分析。

Comprehensive analysis of the role of immune-related PANoptosis lncRNA model in renal clear cell carcinoma based on RNA transcriptome and single-cell sequencing.

机构信息

Department of Urology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China.

出版信息

Oncol Res. 2023 Jun 27;31(4):543-567. doi: 10.32604/or.2023.029563. eCollection 2023.

DOI:10.32604/or.2023.029563
PMID:37415739
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10319599/
Abstract

The high immune infiltration and heterogeneity of the microenvironment in clear cell renal cell carcinoma (ccRCC) result in the variability of prognosis and clinical response. While PANoptosis has strong immunogenicity and is worthy of further study. In this study, data from The Cancer Genome Atlas database was used to obtain immune-related PANoptosis lncRNAs with prognostic value. Subsequently, the role of these lncRNAs in cancer immunity, progression and the therapeutic response was analyzed, and a new prediction model was constructed. Additionally, we further explored the biological value of PANoptosis-related lncRNAs using single-cell data from the Gene Expression Omnibus database. PANoptosis-associated lncRNAs were significantly associated with clinical outcome, immune infiltration, antigen presentation and treatment response in ccRCC. Notably, the risk model, which is based on these immune-related PANoptosis lncRNAs, showed good predictive performance. Subsequent studies on LINC00944 and LINC02611 revealed their high expression in ccRCC and significant correlation with cancer cell migration and invasion. Single-cell sequencing further validated these results and revealed the potential association between LINC00944 and T-cell infiltration and programmed cell death. In conclusion, this study identified the role of immune-related PANoptosis lncRNAs in ccRCC and provided a new risk stratification approach. Furthermore, it highlights the potential of LINC00944 as a prognostic biomarker.

摘要

高免疫浸润和透明细胞肾细胞癌 (ccRCC) 微环境的异质性导致预后和临床反应的可变性。而 PANoptosis 具有很强的免疫原性,值得进一步研究。在这项研究中,使用 The Cancer Genome Atlas 数据库的数据获得具有预后价值的免疫相关 PANoptosis lncRNAs。随后,分析这些 lncRNAs 在癌症免疫、进展和治疗反应中的作用,并构建新的预测模型。此外,我们还使用来自 Gene Expression Omnibus 数据库的单细胞数据进一步探讨了 PANoptosis 相关 lncRNAs 的生物学价值。PANoptosis 相关 lncRNAs 与 ccRCC 的临床结局、免疫浸润、抗原呈递和治疗反应显著相关。值得注意的是,基于这些免疫相关 PANoptosis lncRNAs 的风险模型显示出良好的预测性能。对 LINC00944 和 LINC02611 的后续研究表明,它们在 ccRCC 中高表达,与癌细胞迁移和侵袭显著相关。单细胞测序进一步验证了这些结果,并揭示了 LINC00944 与 T 细胞浸润和程序性细胞死亡之间的潜在关联。总之,本研究确定了免疫相关 PANoptosis lncRNAs 在 ccRCC 中的作用,并提供了一种新的风险分层方法。此外,它突出了 LINC00944 作为预后生物标志物的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/aeb8e5bcf2bb/OncolRes-31-29563-s004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/52ecf1fb0232/OncolRes-31-29563-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/443bc89712b8/OncolRes-31-29563-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/35aede73f8a4/OncolRes-31-29563-f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/d6733c6aee3e/OncolRes-31-29563-f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/ef6180e1de5b/OncolRes-31-29563-f005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/c640a95f5da7/OncolRes-31-29563-f006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/997daed29e94/OncolRes-31-29563-f007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/19c67b8bf190/OncolRes-31-29563-f008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/0869cc0e065e/OncolRes-31-29563-f009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/80c7fea4c04d/OncolRes-31-29563-f010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/e08996ec7e7e/OncolRes-31-29563-f011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/879c05fafd6e/OncolRes-31-29563-f012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/44d07b468989/OncolRes-31-29563-f013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/2f44c3bc7f9f/OncolRes-31-29563-f014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/0117f827301e/OncolRes-31-29563-f015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/c5cdb66fcd3f/OncolRes-31-29563-s001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/02811f0a3c2f/OncolRes-31-29563-s002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/18dd5b97ac9b/OncolRes-31-29563-s003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/aeb8e5bcf2bb/OncolRes-31-29563-s004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/52ecf1fb0232/OncolRes-31-29563-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/443bc89712b8/OncolRes-31-29563-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/35aede73f8a4/OncolRes-31-29563-f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/d6733c6aee3e/OncolRes-31-29563-f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/ef6180e1de5b/OncolRes-31-29563-f005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/c640a95f5da7/OncolRes-31-29563-f006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/997daed29e94/OncolRes-31-29563-f007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/19c67b8bf190/OncolRes-31-29563-f008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/0869cc0e065e/OncolRes-31-29563-f009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/80c7fea4c04d/OncolRes-31-29563-f010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/e08996ec7e7e/OncolRes-31-29563-f011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/879c05fafd6e/OncolRes-31-29563-f012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/44d07b468989/OncolRes-31-29563-f013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/2f44c3bc7f9f/OncolRes-31-29563-f014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/0117f827301e/OncolRes-31-29563-f015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/c5cdb66fcd3f/OncolRes-31-29563-s001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/02811f0a3c2f/OncolRes-31-29563-s002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/18dd5b97ac9b/OncolRes-31-29563-s003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a931/10319599/aeb8e5bcf2bb/OncolRes-31-29563-s004.jpg

相似文献

1
Comprehensive analysis of the role of immune-related PANoptosis lncRNA model in renal clear cell carcinoma based on RNA transcriptome and single-cell sequencing.基于 RNA 转录组和单细胞测序的免疫相关 PANoptosis lncRNA 模型在肾透明细胞癌中作用的综合分析。
Oncol Res. 2023 Jun 27;31(4):543-567. doi: 10.32604/or.2023.029563. eCollection 2023.
2
Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.基于 TME 相关 lncRNAs 的计算构建用于预测透明细胞肾细胞癌的预后和免疫治疗反应的标志物。
J Clin Lab Anal. 2022 Aug;36(8):e24582. doi: 10.1002/jcla.24582. Epub 2022 Jul 8.
3
A Novel Defined PANoptosis-Related miRNA Signature for Predicting the Prognosis and Immune Characteristics in Clear Cell Renal Cell Carcinoma: A miRNA Signature for the Prognosis of ccRCC.一种新型的定义性 PANoptosis 相关 miRNA 特征可预测透明细胞肾细胞癌的预后和免疫特征:用于预测 ccRCC 预后的 miRNA 特征。
Int J Mol Sci. 2023 May 28;24(11):9392. doi: 10.3390/ijms24119392.
4
A Novel Tumor Mutation Burden Related lncRNA Signature Identified Prognosis and Tumor Immune Microenvironment Features in Clear Cell Renal Cell Carcinoma.一种新型肿瘤突变负担相关 lncRNA 标志物鉴定出透明细胞肾细胞癌的预后和肿瘤免疫微环境特征。
Comb Chem High Throughput Screen. 2023;26(8):1503-1518. doi: 10.2174/1386207325666220926123923.
5
Identification and experimental validation of a tumor-infiltrating lymphocytes-related long noncoding RNA signature for prognosis of clear cell renal cell carcinoma.鉴定和实验验证与肿瘤浸润淋巴细胞相关的长非编码 RNA 标志物,用于预测透明细胞肾细胞癌的预后。
Front Immunol. 2022 Nov 24;13:1046790. doi: 10.3389/fimmu.2022.1046790. eCollection 2022.
6
Construction of a Novel Immune-Related lncRNA Pair Signature with Prognostic Significance for Kidney Clear Cell Renal Cell Carcinoma.构建具有预后意义的新型免疫相关 lncRNA 对用于肾透明细胞肾细胞癌。
Dis Markers. 2021 Sep 1;2021:8800358. doi: 10.1155/2021/8800358. eCollection 2021.
7
Comprehensive analysis of necroptosis-related lncRNA signature with potential implications in tumor heterogeneity and prediction of prognosis in clear cell renal cell carcinoma.全面分析与 necroptosis 相关的 lncRNA 特征,这些特征可能与肿瘤异质性有关,并对 clear cell renal cell carcinoma 的预后有预测作用。
Eur J Med Res. 2023 Jul 14;28(1):236. doi: 10.1186/s40001-023-01194-4.
8
Utilizing a novel model of PANoptosis-related genes for enhanced prognosis and immune status prediction in kidney renal clear cell carcinoma.利用一种新的 PANoptosis 相关基因模型增强肾透明细胞癌的预后和免疫状态预测。
Apoptosis. 2024 Jun;29(5-6):681-692. doi: 10.1007/s10495-023-01932-3. Epub 2024 Jan 28.
9
Integrated analysis on the N6-methyladenosine-related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma.N6-甲基腺苷相关长非编码 RNA 预后signature、免疫检查点和免疫细胞浸润的综合分析在透明细胞肾细胞癌中的研究。
Immun Inflamm Dis. 2021 Dec;9(4):1596-1612. doi: 10.1002/iid3.513. Epub 2021 Aug 25.
10
Construction of a ferroptosis-related signature based on seven lncRNAs for prognosis and immune landscape in clear cell renal cell carcinoma.基于七个 lncRNAs 的铁死亡相关特征构建用于透明细胞肾细胞癌预后和免疫图谱分析。
BMC Med Genomics. 2022 Dec 17;15(1):263. doi: 10.1186/s12920-022-01418-2.

引用本文的文献

1
The molecular mechanisms and therapeutic implications of PANoptosis in ischemic diseases.PAN细胞焦亡在缺血性疾病中的分子机制及治疗意义
Apoptosis. 2025 Sep 7. doi: 10.1007/s10495-025-02157-2.
2
Pan-cancer analysis and experimental validation revealed the prognostic role of ZNF83 in renal and lung cancer cohorts.泛癌分析和实验验证揭示了ZNF83在肾癌和肺癌队列中的预后作用。
Discov Oncol. 2025 Jul 15;16(1):1335. doi: 10.1007/s12672-025-03026-9.
3
Identification of a PANoptosis-related long noncoding rna risk signature for prognosis and immunology in colon adenocarcinoma.

本文引用的文献

1
Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.构建并验证一种与铜死亡相关的长链非编码RNA特征作为结肠癌的新型稳健预后模型。
Front Oncol. 2022 Jul 28;12:961213. doi: 10.3389/fonc.2022.961213. eCollection 2022.
2
Identification and validation of an immune-related gene prognostic signature for clear cell renal carcinoma.鉴定和验证用于透明细胞肾细胞癌的免疫相关基因预后特征。
Front Immunol. 2022 Jul 22;13:869297. doi: 10.3389/fimmu.2022.869297. eCollection 2022.
3
Programmed Cell Death Tunes Tumor Immunity.
鉴定一种与全凋亡相关的长链非编码RNA风险特征用于预测结肠腺癌的预后和免疫情况
BMC Cancer. 2025 Apr 10;25(1):662. doi: 10.1186/s12885-025-14021-2.
4
Emerging role of PANoptosis in kidney diseases: molecular mechanisms and therapeutic opportunities.PAN细胞焦亡在肾脏疾病中的新作用:分子机制与治疗机遇
Apoptosis. 2025 Apr;30(3-4):579-596. doi: 10.1007/s10495-024-02072-y. Epub 2025 Jan 20.
5
Identification of a novel cellular senescence-related lncRNA signature for prognosis and immune response in osteosarcoma.鉴定一种用于骨肉瘤预后和免疫反应的新型细胞衰老相关长链非编码RNA特征
Transl Cancer Res. 2024 Jul 31;13(7):3742-3759. doi: 10.21037/tcr-24-163. Epub 2024 Jul 8.
6
Identification of PANoptosis-relevant subgroups and predicting signature to evaluate the prognosis and immune landscape of patients with biliary tract cancer.识别与PAN细胞焦亡相关的亚组并预测特征以评估胆管癌患者的预后和免疫格局。
Hepatol Int. 2024 Dec;18(6):1792-1803. doi: 10.1007/s12072-024-10718-x. Epub 2024 Aug 10.
7
Comprehensive analysis of lncRNA-associated ceRNA network reveals novel potential prognostic regulatory axes in glioblastoma multiforme.长链非编码 RNA 相关 ceRNA 网络的综合分析揭示胶质母细胞瘤中新型潜在预后调控轴。
J Cell Mol Med. 2024 Jun;28(11):e18392. doi: 10.1111/jcmm.18392.
8
A pan-cancer analysis of the oncogenic and immunological roles of transglutaminase 1 (TGM1) in human cancer.转谷氨酰胺酶1(TGM1)在人类癌症中的致癌和免疫作用的泛癌分析
J Cancer Res Clin Oncol. 2024 Mar 12;150(3):123. doi: 10.1007/s00432-024-05640-6.
9
A PANoptosis pattern to predict prognosis and immunotherapy response in head and neck squamous cell carcinoma.一种用于预测头颈部鳞状细胞癌预后和免疫治疗反应的PAN凋亡模式。
Heliyon. 2024 Feb 27;10(5):e27162. doi: 10.1016/j.heliyon.2024.e27162. eCollection 2024 Mar 15.
10
PANoptosis-related long non-coding RNA signature to predict the prognosis and immune landscapes of pancreatic adenocarcinoma.用于预测胰腺腺癌预后和免疫格局的PANoptosis相关长链非编码RNA特征
Biochem Biophys Rep. 2023 Dec 7;37:101600. doi: 10.1016/j.bbrep.2023.101600. eCollection 2024 Mar.
程序性细胞死亡调节肿瘤免疫。
Front Immunol. 2022 Mar 30;13:847345. doi: 10.3389/fimmu.2022.847345. eCollection 2022.
4
Identification of a Novel Glycosyltransferase Prognostic Signature in Hepatocellular Carcinoma Based on LASSO Algorithm.基于LASSO算法的肝细胞癌新型糖基转移酶预后特征的鉴定
Front Genet. 2022 Mar 9;13:823728. doi: 10.3389/fgene.2022.823728. eCollection 2022.
5
Long noncoding RNA NEAT1 promotes ferroptosis by modulating the miR-362-3p/MIOX axis as a ceRNA.长链非编码 RNA NEAT1 通过作为 ceRNA 调节 miR-362-3p/MIOX 轴促进铁死亡。
Cell Death Differ. 2022 Sep;29(9):1850-1863. doi: 10.1038/s41418-022-00970-9. Epub 2022 Mar 25.
6
Prognostic value and immune relevancy of a combined autophagy-, apoptosis- and necrosis-related gene signature in glioblastoma.胶质母细胞瘤中联合自噬、凋亡和坏死相关基因特征的预后价值及其免疫相关性。
BMC Cancer. 2022 Mar 3;22(1):233. doi: 10.1186/s12885-022-09328-3.
7
Prognostic Value and Correlation With Tumor Immune Infiltration of a Novel Metabolism-Related Gene Signature in Pancreatic Cancer.一种新型代谢相关基因特征在胰腺癌中的预后价值及其与肿瘤免疫浸润的相关性
Front Oncol. 2022 Jan 19;11:757791. doi: 10.3389/fonc.2021.757791. eCollection 2021.
8
Pyroptosis Regulators and Tumor Microenvironment Infiltration Characterization in Clear Cell Renal Cell Carcinoma.肾透明细胞癌中焦亡调节因子与肿瘤微环境浸润特征
Front Oncol. 2022 Jan 5;11:774279. doi: 10.3389/fonc.2021.774279. eCollection 2021.
9
PANoptosis: A New Insight Into Oral Infectious Diseases.PANoptosis:口腔感染性疾病的新视角。
Front Immunol. 2021 Dec 14;12:789610. doi: 10.3389/fimmu.2021.789610. eCollection 2021.
10
Necroptosis-Related lncRNAs: Predicting Prognosis and the Distinction between the Cold and Hot Tumors in Gastric Cancer.坏死性凋亡相关长链非编码RNA:预测胃癌预后及区分冷肿瘤与热肿瘤
J Oncol. 2021 Nov 8;2021:6718443. doi: 10.1155/2021/6718443. eCollection 2021.